Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P K Schädlich

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Gesundheitswesen (Bundesverband Der Arzte Des Offentlichen Gesundheitsdienstes (Germany))|February 1, 1993
[Quality of event data in detection of unwanted drug side-effects in general practice of established physicians]P K Schädlich
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|December 1, 1994
Self-sufficiency--20 years onP K Schädlich
Pharmacoeconomics|May 7, 1998
The cost effectiveness of acamprosate in the treatment of alcoholism in Germany. Economic evaluation of the Prevention of Relapse with Acamprosate in the Management of Alcoholism (PRAMA) StudyP K Schädlich, J G Brecht
Sozial- Und Praventivmedizin|January 1, 1997
[Cost-effectiveness analysis of prevention of reinfarction using low-dose acetylsalicylic acid; model calculation]P K Schädlich, J G Brecht
Pharmacoeconomics|April 5, 2000
Economic evaluation of specific immunotherapy versus symptomatic treatment of allergic rhinitis in GermanyP K Schädlich, J G Brecht
Medizinische Klinik (Munich, Germany : 1983)|August 15, 1997
[Cost effectiveness of bisoprolol in heart failure. Economic evaluation of the Cardiac Insufficiency Bisoprolol Study (CIBIS) for Germany]P K Schädlich, B Paschen, J G Brecht
Pharmacoeconomics|May 27, 1999
Cost-effectiveness analysis of ramipril in heart failure after myocardial infarction. Economic evaluation of the Acute Infarction Ramipril Efficacy (AIRE) study for Germany from the perspective of Statutory Health InsuranceP K Schädlich, E Huppertz, J G Brecht
Pharmacoeconomics|October 4, 1996
Alcoholism. The cost of illness in the Federal Republic of GermanyJ G Brecht, F Poldrugo, P K Schädlich
Pharmacoeconomics|December 8, 1997
Economic evaluation of the Cardiac Insufficiency Bisoprolol Study for the Federal Republic of GermanyP K Schädlich, B Paschen, J G Brecht
Deutsche Medizinische Wochenschrift (1946)|March 12, 2009
[Quality of life and treatment satisfaction in patients being treated with long-acting insulin analogues]E G Hagenmeyer, P K Schädlich, A D Köster, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Gesundheitswesen (Bundesverband Der Arzte Des Offentlichen Gesundheitsdienstes (Germany))|February 1, 1993
[Quality of event data in detection of unwanted drug side-effects in general practice of established physicians]P K Schädlich
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|December 1, 1994
Self-sufficiency--20 years onP K Schädlich
Pharmacoeconomics|May 7, 1998
The cost effectiveness of acamprosate in the treatment of alcoholism in Germany. Economic evaluation of the Prevention of Relapse with Acamprosate in the Management of Alcoholism (PRAMA) StudyP K Schädlich, J G Brecht
Sozial- Und Praventivmedizin|January 1, 1997
[Cost-effectiveness analysis of prevention of reinfarction using low-dose acetylsalicylic acid; model calculation]P K Schädlich, J G Brecht
Pharmacoeconomics|April 5, 2000
Economic evaluation of specific immunotherapy versus symptomatic treatment of allergic rhinitis in GermanyP K Schädlich, J G Brecht
Medizinische Klinik (Munich, Germany : 1983)|August 15, 1997
[Cost effectiveness of bisoprolol in heart failure. Economic evaluation of the Cardiac Insufficiency Bisoprolol Study (CIBIS) for Germany]P K Schädlich, B Paschen, J G Brecht
Pharmacoeconomics|May 27, 1999
Cost-effectiveness analysis of ramipril in heart failure after myocardial infarction. Economic evaluation of the Acute Infarction Ramipril Efficacy (AIRE) study for Germany from the perspective of Statutory Health InsuranceP K Schädlich, E Huppertz, J G Brecht
Pharmacoeconomics|October 4, 1996
Alcoholism. The cost of illness in the Federal Republic of GermanyJ G Brecht, F Poldrugo, P K Schädlich
Pharmacoeconomics|December 8, 1997
Economic evaluation of the Cardiac Insufficiency Bisoprolol Study for the Federal Republic of GermanyP K Schädlich, B Paschen, J G Brecht
Deutsche Medizinische Wochenschrift (1946)|March 12, 2009
[Quality of life and treatment satisfaction in patients being treated with long-acting insulin analogues]E G Hagenmeyer, P K Schädlich, A D Köster, et al.
Pageof 2